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Abstract
Background: The anti-epileptic drug valproic acid (VPA) has attracted attention as an anti-cancer agent.
Methods: The present study investigated effects of VPA exposure on histone deacetylase (HDAC) inhibition, cell
growth, cell speed, and the degree of Erk1/2 phosphorylation in 10 cell lines (BT4C, BT4Cn, U87MG, N2a, PC12-E2,
CSML0, CSML100, HeLa, L929, Swiss 3T3).
Results: VPA induced significant histone deacetylase (HDAC) inhibition in most of the cell lines, but the degree of
inhibition was highly cell type-specific. Moreover, cell growth, motility and the degree of Erk1/2 phosphorylation
were inhibited, activated, or unaffected by VPA in a cell type-specific manner. Importantly, no relationship was
found between the effects of VPA on HDAC inhibition and changes in the degree of Erk1/2 phosphorylation, cell
growth, or motility. In contrast, VPA-induced modulation of the MAPK pathway downstream of Ras but upstream
of MEK (i.e., at the level of Raf) was important for changes in cell speed.
Conclusions: These results suggest that VPA can modulate the degree of Erk1/2 phosphorylation in a manner
unrelated to HDAC inhibition and emphasize that changes in the degree of Erk1/2 phosphorylation are also
important for the anti-cancer properties of VPA.
Background
Valproic acid (2-n-propylpentanoic acid, VPA) is a com-
mon anti-epileptic drug that is also used for the treat-
ment of bipolar disorder, migraine and neuropathic pain
[1]. Moreover, VPA can modulate several cancer-related
processes, including angiogenesis, immunogenicity, and
invasion, metastasis, differentiation, proliferation and
apoptosis of cancer cells [2]. Recent clinical studies have
demonstrated the chemotherapeutic efficacy of VPA for
the treatment of several types of cancer, including acute
myeloid leukemia, myelodysplastic syndromes [3], and
solid breast and cervix tumors [4].
VPA is a histone deacetylase (HDAC) inhibitor that
alters gene expression, thereby modulating processes
such as cell growth, differentiation and apoptosis [5,6].
The drug is also known to modulate the activity of sev-
eral intracellular enzymes, including mitogen-activated
protein kinases (MAPKs), protein kinase C (PKC) and
glycogen synthase kinase-3b (GSK-3b) [2,7].
Several of the cellular processes modulated by VPA
may be partially regulated by signaling through the
MAPK pathway [8-10]. Signaling through this pathway
is often initiated by activation of membrane-localized
receptors, leading to activation of the GTPase Ras, and
subsequent activation of the MAPK kinase kinase Raf,
the MAPK kinases MEK1/2 and the MAPKs Erk1/2
[11]. Activated Erk1/2 phosphorylate targets in the cyto-
sol and transcription factors in the nucleus [12]. Erk1/2
can also be activated Ras-independently by other
upstream molecules, including protein kinase A (PKA)
and PKC. Furthermore, cells express up to three Raf
types (i.e., A-, B- and c-Raf), which are affected differ-
ently by upstream targets, thereby adding a further level
of complexity to MAPK-mediated signaling [13,14].
The anti-cancer effects of VPA are generally attributed
to its HDAC inhibitory activity. However, these effects
may also be partially caused by alterations in, for exam-
ple, Erk1/2 activity. Interestingly, previous studies have
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shown cell type-specific effects of VPA, both on specific
cellular processes, such as cell migration and prolifera-
tion [15], and on specific enzyme activities, including
Erk1/2 activity [16,17]. The reasons for these cell type-
specific effects, however, are unknown.
The aim of the present study was to investigate the
relationships between VPA-induced changes in HDAC
and Erk1/2 activities, and cell growth and motility. The
results reveal striking cell type-specific differences in the
responses to VPA. Moreover, the effects of VPA on cell
growth, motility and the degree of Erk1/2 phosphoryla-
tion were not related to its effects on HDAC inhibition.
In contrast, modulation of cell growth and motility was
in some cell lines related to changes in the degree of




Cells were grown in a humidified atmosphere at 37°C,
5% CO2. The rat glioma cell lines BT4C and BT4Cn,
the human glioma cell line U87MG (a gift from Dr.
Nina Pedersen, Copenhagen University Hospital Rig-
shospitalet, Copenhagen, Denmark), the mouse neuro-
blastoma cell line N2a, the mouse adenocarcinoma cell
lines CSML0 and CSML100, the human adenocarci-
noma cell line HeLa, and the mouse fibroblastoid cell
lines Swiss 3T3 and L929 were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% (v/v) heat-inactivated fetal calf serum (FCS), 2 mM
GlutaMAX, 100 U/ml penicillin, 100 μg/ml streptomy-
cin and 2.5 μg/ml fungizone (all from Invitrogen,
Taastrup, Denmark). Cells were dislodged with trypsin/
EDTA in modified Puck’s saline (Invitrogen).
The rat pheochromocytoma cell line PC12-E2 was
grown in DMEM supplemented with 5% (v/v) FCS, 10%
(v/v) horse serum, 2 mM GlutaMAX, 100 U/ml penicil-
lin and 100 μg/ml streptomycin (Invitrogen). Cells were
dislodged by tapping the culture flask.
Cell transfection
Stable transfection of L929 with the pGV16 vector
encoding constitutively active rat H-Ras (G12V; a gift
from Prof. Berthe Willumsen, Department of Biology,
Faculty of Science, University of Copenhagen, Copenha-
gen, Denmark) was obtained using Lipofectin (Invitro-
gen). After transfection, cells were grown in medium
containing 0.75 mg/ml geneticin (Invitrogen) for
3 weeks. Six geneticin-resistant clones with high H-
RasG12V expression were selected, propagated, pooled
and used as stock for subsequent experiments. Ten ran-
domly selected clones stably transfected with the empty
pGV16 vector were selected, propagated, pooled and
used as control cells.
Transient transfections of cells with the pGV16 vector
encoding dominant-negative rat H-Ras (S17N; a gift
from Dr. Berthe Willumsen), the pRK5 vector encoding
constitutively active rat MEK2 (S222E/S226E; a gift from
Dr. Klaus Seedorf, Hagedorn Research Institute, Gen-
tofte, Denmark), or the corresponding empty vectors
were performed using FuGene 6 (Roche Diagnostics,
Mannheim, Germany) or Lipofectin 2000 (Invitrogen).
Transient transfections were performed as co-transfec-
tions with low amounts of the pEGFP-N1 vector (Clon-
tech, Saint-Germain-en-Laye, France). Consequently,
transfected cells were identified from their expression of
enhanced green fluorescent protein. Cells were replated
for subsequent experiments ~24 h after transfection.
VPA treatment
A stock solution of 3 M VPA (Sigma-Aldrich, Copenha-
gen, Denmark) was prepared in dimethylsulfoxide
(DMSO), and all assays were performed in the presence
of 0.1% (v/v) DMSO in the presence or absence of VPA.
Immunoblotting
Cells were plated in 60 mm culture dishes (Nunc, Ros-
kilde, Denmark) at a density of 0.25-0.75 × 106 cells/
dish and grown in medium containing 0-3 mM VPA for
up to 48 h. In experiments in which cells were exposed
to a MEK inhibitor (PD98059; Cell Signaling, Danvers,
MA), the compound was added to the cultures 1 h
before cell lysis. Following incubation, cells were rinsed
in ice-cold PBS and collected in radioimmunoprecipita-
tion assay lysis buffer supplemented with Complete,
EDTA-free Protease Inhibitor Cocktail (Roche Diagnos-
tics) and Phosphatase Inhibitor Cocktail Set III (Calbio-
chem). Proteins were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred to Immobilon-P membranes (Millipore,
Billerica, MA). The membranes were blocked in PBS
containing 0.1% (v/v) Tween-20 and 5% (w/v) bovine
serum albumin.
Following incubation with primary antibodies, all
membranes were incubated with horseradish peroxi-
dase-conjugated goat anti-rabbit antibody (Cell Signal-
ing), visualized by chemiluminescence (SuperSignal
West Dura Extended Duration Substrate, Pierce Bio-
technology, Rockford, IL) using a GeneGnome (Syngene,
Cambridge, UK), and quantified using the accompanying
GenTools software.
For estimation of Erk1/2 phosphorylation, membranes
were probed with anti-phospho-Erk1/2 (Thr202/Tyr204)
antibody (Cell Signaling). After visualization, the
membranes were stripped (30 min, 50°C) in 62.5 mM
Tris-HCl, pH 6.8, 2% (w/v) SDS and 50 mM 1,4-dithio-
L-threitol, blocked, and reprobed with anti-pan-Erk1/2
antibody (Cell Signaling). Ras expression was
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determined using anti-H-, K- and N-Ras antibodies (Cell
Signaling). Histone acetylation was determined using
anti-acetyl histone H3 (Lys9/Lys14) antibody (Cell Sig-
naling). Ras and histone H3 acetylation immunoblots
were stripped and reprobed with anti-actin antibody
(Sigma-Aldrich).
Cell growth
Cell growth was quantified from crystal violet stainings.
5 × 103 cells/well were plated in 96-well microwell
plates (Nunc) and grown in medium containing 0-3 mM
VPA for 48 h, with each treatment replicated in 6 wells/
plate. Cells were fixed in 3.7% (v/v) formalin and 1% (v/
v) methanol in PBS, and stained with 0.04% (w/v) crystal
violet in 4% (v/v) ethanol. Finally, the cell-bound crystal
violet was solubilized using 1% (w/v) SDS, and optical
density was measured at 600 nm.
Measurement of individual cell motility
6-15 × 103 cells/well were plated in 6-well culture
plates (Nunc) and grown in medium containing 0-3
mM VPA. Time-lapse video-recordings were per-
formed using a computer-assisted microscope worksta-
tion as previously described [18]. Simultaneous,
sequential recordings from 8-20 microscopic fields/well
were performed at 1-10 min intervals for 20-80 min.
Evaluation of individual cell motility was performed
using the image processing software PRIMA (Protein
Laboratory, Copenhagen University, Denmark). 50-200
cells from each well were tracked, and the data were
used for the calculation of the mean-cell speed and the
mean-squared cell displacement (<d2>) as previously
described [19].
Statistics
Results are expressed as mean ± SEM, calculated on the
basis of the number of experiments. Unless indicated
otherwise, statistical analyses were performed on non-
normalized data using one-way repeated-measures
analysis of variance (ANOVA) followed by the Tukey-
Kramer multiple comparison test. Immunoblots were
evaluated using the Wilcoxon signed rank test.
Estimates of IC25 and IC50 values were based on the
interpolation of data from log dose-response curves.
Correlations were performed as Pearson correlations.
All p-values refer to two-tailed calculations. *, ** and ***
indicate p < 0.05, 0.01 and 0.001, respectively.
Results
Effects of VPA on the degree of Erk1/2 phosphorylation
and histone H3 acetylation
Erk1/2 activity was investigated in 10 cell lines, includ-
ing BT4C, BT4Cn, U87MG, N2a, PC12-E2, CSML0,
CSML100, HeLa, Swiss 3T3 and L929, by estimating the
degree of Erk1/2 phosphorylation by immunoblotting.
In the absence of VPA, BT4C, BT4Cn, U87MG, and
PC12-E2 exhibited high Erk1/2 phosphorylation levels.
L929, Swiss 3T3 and CSML0 exhibited intermediate
levels, and N2a, CSML100 and HeLa exhibited low
levels (Figure 1a). Figure 1b and 1c show the relative
changes in the degree of Erk1/2 phosphorylation in the
respective cell lines in response to VPA (3 mM, 48 h).
Erk1/2 phosphorylation was significantly decreased in
CSML0 and L929, significantly increased in CSML100,
BT4Cn and N2a, and not significantly affected in BT4C,
U87MG, PC12-E2, HeLa and Swiss 3T3.
VPA is a known HDAC inhibitor. Figure 1d shows
the degree of acetylation of histone H3 in the 10 cell
lines under control conditions determined by immuno-
blotting. All cell lines exhibited low acetylation levels
under control conditions (Figure 1d).
VPA significantly increased the degree of acetylation
in 8 of the 10 cell lines (Figure 1e and 1f). The changes
in acetylation ranged from an approximately three-fold
increase (U87MG) to an ~13-fold increase (BT4C; Fig-
ure 1e).
In conclusion, VPA has highly cell type-specific effects
on the degree of HDAC inhibition and on changes in
the degree of Erk1/2 phosphorylation. Furthermore, the
effects of VPA on the degree of Erk1/2 phosphorylation
and HDAC inhibition were not related to the degree of
Erk1/2 phosphorylation and acetylation in the absence
of the drug. Finally, no relationship was found between
the effects of VPA on HDAC inhibition and the degree
of Erk1/2 phosphorylation. Thus, VPA-induced changes
in the degree of Erk1/2 phosphorylation cannot be
explained by the effects of the drug on HDAC activity,
although HDAC inhibition may contribute to the
observed effects.
Effects of VPA on cell growth
Figure 2 shows that VPA dose-dependently changed the
growth of all investigated cell lines. Nine cell lines
exhibited IC25 values ranging from 0.43 to 1.83 mM
(Table 1), whereas the growth of a single cell line,
U87MG, was significantly elevated upon exposure to
0.75 mM VPA.
A correlation analysis of the data presented in Figure
1 and 2 revealed no significant correlations between the
effects of VPA on HDAC inhibition and cell growth or
between the degree of Erk1/2 phosphorylation and cell
growth (Figure S4). However, four of the five cell lines
that did not demonstrate significant changes in the
degree of Erk1/2 phosphorylation in response to VPA
(Figure 1b) did not have IC50 values for growth within
the tested concentration range (below 3 mM; Table 1),
whereas all five cell lines demonstrating significant
changes in the degree of Erk1/2 phosphorylation in
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response to VPA had IC50 values for growth below
3 mM. These results demonstrate a significant relation-
ship between the effects of VPA o the degree of Erk1/2
phosphorylation and cell growth (p < 0.05, Fisher’s exact
test).
In conclusion, VPA induced highly cell type-specific
effects on cell growth. Furthermore, no apparent rela-
tionship was observed between the effects of VPA on
HDAC inhibition and cell growth, whereas VPA was
likely to affect the growth of a given cell type if it
affected the degree of Erk1/2 phosphorylation in that
cell type at physiologically relevant concentrations.
Effects of VPA on individual cell motility and the degree
of Erk1/2 phosphorylation in L929 cells
Erk1/2 are known to regulate cell motility [20]. In L929
cells, VPA inhibits the degree of Erk1/2 phosphorylation
(Figure 1) and cell speed [21]. Therefore, a potential
Figure 1 Effects of VPA on the degree of Erk1/2 phosphorylation and histone H3 acetylation. (a, d) Representative immunoblots
showingdegree of Erk1/2 phosphorylation (a) and histone H3 acetylation (d) in cells grown in the absence of VPA for 48 h. (c, f) Representative
immunoblots showing changes in the degree of Erk1/2 phosphorylation (c) and histone H3 acetylation (f) in cells grown in the absence or
presence of 3 mM VPA for 48 h. The corresponding levels of Erk1/2 (a, c) or actin (d, f) are shown as loading controls. Protein levels are not
comparable between different cell lines. As a positive control for histone H3 acetylation, Swiss 3T3 cells were treated with trichostatin A (TSA;
400 nM, 24 h) (d, first lane). (b, e) Bar graphs showing the effects of VPA (3 mM, 48 h) on the degree of Erk1/2 phosphorylation (b) and histone
H3 acetylation (e). The degree of Erk1/2 phosphorylation and histone H3 acetylation were normalized to the corresponding cells untreated with
VPA from 6-12 individual experiments.
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relationship between the effects of VPA on the degree of
Erk1/2 phosphorylation and cell motility was investi-
gated further in L929 cells.
Figure 3a shows time-dependent effects of 3 mM
VPA on the mean-cell speed of L929 cells. The speed
was significantly reduced after 1 h exposure to the drug.
After 24-48 h exposure, further reductions in cell speed
were observed. Figure 3b shows data from the time-
response experiments, in which VPA was directly added
to the culture medium during the motility recordings.
Using this approach, a reduction in cell displacement
was observed for VPA-treated cells ~20 min after drug
addition compared with control cultures. These observa-
tions demonstrate that VPA caused biphasic, time-related
inhibition of the cell speed of L929 cells, characterized by
an initial, rapid inhibition followed by a further inhibition
at later time-points.
Figure 3c and 3e show time-response effects of VPA
on the degree of Erk1/2 phosphorylation. A 1 h expo-
sure to 3 mM VPA significantly decreased the degree of
Erk1/2 phosphorylation. After 6 and 24 h, the degree of
Erk1/2 phosphorylation decreased further. Figure 3d
and 3f show dose-response curves of the effects of VPA
on Erk1/2 phosphorylation. VPA dose-dependently
inhibited the degree of Erk1/2 phosphorylation, with
estimated IC25 and IC50 values of ~0.24 and 0.58 mM,
respectively. A comparison of Figure 3a and 3d revealed
that the time-course of the effects of VPA on the degree
of Erk1/2 phosphorylation resembled that observed for
the inhibition of cell speed, suggesting that VPA par-
tially modulated cell speed through modulation of the
degree of Erk1/2 phosphorylation.
Following the studies of L929 cells, the motility of the
remaining nine cell lines was investigated. Figure 4
shows that VPA significantly and dose-dependently
inhibited the speed of N2a, U87MG and PC12-E2 cells,
stimulated the speed of BT4Cn cells, and did not affect
the speed of the remaining five cell lines (BT4C,
CSML0, CSML100, HeLa and Swiss 3T3).
Figure 2 Effects of VPA on cell growth. Dose-response curves showing the effects of VPA on cell growth. Cells were exposed to VPA (0-3 mM,
48 h) before growth was determined using crystal violet staining. Results were normalized to the corresponding cells untreated with VPA from
four independent experiments.





BT4C 1.52 (1.12 - 1.84) >3.0 -
BT4Cn 1.06 (0.95 - 1.20) 2.67 (2.37 - 2.98)
U87MG >3.0 - >3.0 -
N2a 0.65 (0.54 - 0.72) 2.73 (2.11 - 3.19)
PC12-E2 1.83 (1.67 - 1.99) >3.0 -
CSML0 0.43 (0.24 - 0.53) 1.01 (0.94 - 1.08)
CSML100 0.46 (0.32 - 0.58) 1.22 (0.98 - 1.41)
HeLa 0.70 (0.62 - 0.75) 2.75 (2.54 - 3.01)
Swiss 3T3 1.35 (1.22 - 1.47) >3.0 -
L929 0.43 (0.32 - 0.51) 1.13 (0.97 - 1.29)
IC25 and IC50 values for the effects of VPA on cell growth calculated from
interpolations of data. a: Numbers in parentheses indicate interpolated values
for IC25 or IC50 ± SEM (based on four independent experiments).
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Effects of VPA on individual cell motility by modulation
of signal transduction upstream of Erk1/2
The GTPase Ras is an upstream activator of the MAPK
pathway [11]. To determine whether VPA modulated
the MAPK pathway upstream or downstream of Ras,
the effects of VPA were investigated in L929 cells
expressing constitutively active Ras (caRas). Figure 5a
shows micrographs of L929 cells not expressing or
expressing caRas and grown in the presence or absence
of VPA. Control-transfected cells adopted a stellate phe-
notype with an increased area when treated with
VPA (Figure 5a, two leftmost images), whereas caRas-
expressing cells were more round and loosely attached
(Figure 5a, two topmost images), a typical phenotype of
Figure 3 Effects of VPA on individual cell motility and the degree of Erk1/2 phosphorylation in L929 cells. (a) Time-response curve
showing the effects VPA on mean-cell speed of L929 cells exposed to 3 mM VPA. Cells were recorded for 20 min at 2 min intervals. The mean-
cell speed of the individual cells was normalized to the corresponding cells untreated with VPA from four to seven independent experiments. (b)
Time-response curve from a representative experiment showing the effect of VPA on mean-squared displacement (<d2>). At the indicated time-
point, VPA was added to the cell culture to a final concentration of 3 mM. Control (open circle) and VPA-treated (solid circle) cells were recorded
at 2 and 1 min intervals, respectively. (c-f) Effects of VPA on the degree of Erk1/2 phosphorylation in L929 cells. (c, e) Representative
immunoblots showing the degree of Erk1/2 phosphorylation in cells grown in the presence or absence of 3 mM VPA for 20 min to 24 h (c) or
the presence or absence of 0-3 mM VPA for 24 h (e). The corresponding levels of Erk1/2 are shown as loading controls. (d, f) Time- and dose-
response graphs showing the effects of 3 mM VPA for 0-24 h (d) or 0-3 mM VPA for 24 h (f) on the degree of Erk1/2 phosphorylation, which
was normalized to the corresponding cells untreated with VPA from four to five individual experiments.
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Figure 4 Effects of VPA on individual cell motility. Bar graphs showing the effects of VPA on the cell speed. Cells were exposed to VPA (0-3
mM, 48 h) before individual cell motility was recorded. BT4C and BT4Cn cells were recorded for 20 min at 5 min intervals. The remaining cell
lines were recorded for 40 min at 10 min intervals. Results were normalized to the corresponding cells untreated with VPA from four to six
independent experiments, each being based on analysis 50-200 cells/treatment.
Gotfryd et al. BMC Cancer 2010, 10:383
http://www.biomedcentral.com/1471-2407/10/383
Page 7 of 12
Figure 5 Effects of VPA on individual cell motility by modulation of signal transduction upstream of Erk1/2. (a) Micrographs of L929
cells stably expressing or not expressing constitutively active Ras (caRas) and grown in the absence or presence of VPA (3 mM, 48 h). (b)
Representative immunoblot showing the degree of Erk1/2 phosphorylation in cells grown in the presence or absence of VPA (3 mM, 48 h). (c)
Bar graph showing the mean-cell speed of cells grown in the presence or absence of VPA (3 mM, 48 h). (d) Bar graph showing the mean-cell
speed of L929 cells transiently expressing or not expressing constitutively active MEK2 (caMEK2). Cells grown in the presence or absence of VPA
(3 mM, 4 h) were recorded 48 h after transfection. Data presented in c and d are from cells recorded for 50 min at 10 min intervals. Results were
normalized to the corresponding controls from four individual experiments. (e) Representative immunoblot showing the expression of Ras in
BT4Cn cells transiently expressing or not expressing dominant-negative Ras (dnRas). Lysates were prepared 48 h after transfection. (f) Bar graph
showing the mean-cell speed of BT4Cn cells grown in the presence or absence of VPA (3 mM, 4 or 24 h) and recorded for 20 min at 2 min
intervals (48 h after transfection). Results were normalized to the corresponding controls from 6 individual experiments. (g) Representative
immunoblot showing the degree of Erk1/2 phosphorylation in BT4Cn cells grown in the presence or absence of VPA (3 mM, 48 h) and treated
or untreated with 25 μM PD98059 for 1 h. (h) Bar graph showing the mean-cell speed of BT4Cn cells grown in the presence or absence of VPA
(3 mM, 48 h) and treated or untreated with 25 μM PD98059 for 1 h. Recordings were performed for 20 min at 5 min intervals. Results were
normalized to the corresponding controls from eight individual experiments.
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Ras-transformed cells [22]. However, exposure of caRas-
expressing cells to VPA caused them to adopt a pheno-
type similar to control-transfected cells treated with
VPA (Figure 5a, two rightmost images). The immuno-
blot presented in Figure 5b shows that L929 cells
expressing caRas exhibited higher degrees of Erk1/2
phosphorylation than control-transfected cells when
grown in the absence of VPA (Figure 5b, lanes 2 and
1). However, VPA caused equally strong inhibition
of Erk1/2 phosphorylation in control- and caRas-
transfected cells (Figure 5b, lanes 3 and 4). These
results demonstrate that exposure to VPA reversed the
effects of caRas expression on L929 cell morphology
and the degree of Erk1/2 phosphorylation. Cells expres-
sing caRas did not move significantly faster than con-
trol-transfected cells when grown in the absence of VPA
(Figure 5c). The speed of control- and caRas-transfected
cells was similarly inhibited in the presence of VPA
(Figure 5c).
Figure 5d shows the effects of VPA exposure on the
speed of L929 cells expressing constitutively active
MEK2 (caMEK2). Cells expressing caMEK2 did not
move significantly faster than control-transfected cells
grown in the absence of VPA (Figure 5d, p < 0.063).
However, in the presence of VPA, caMEK2-expressing
cells moved significantly faster than control-transfected
cells exposed to VPA (Figure 5d, p < 0.029). Moreover,
the speed of caMEK2-expressing cells was not signifi-
cantly reduced after exposure to VPA (Figure 5d, col-
umn 4 vs. column 2).
To determine whether VPA affected the speed of
BT4Cn cells through effects on the degree of Erk1/2
phosphorylation, the effects of VPA were investigated in
BT4Cn cells expressing dominant-negative Ras (dnRas).
The expression of dnRas was verified by immunoblot-
ting using a polyclonal anti-Ras antibody. As shown in
Figure 5e, Ras immunoreactivity was increased in cells
transfected with the dnRas expression vector, indicating
that the cells expressed dnRas. Figure 5f shows that
exposure of BT4Cn cells to 3 mM VPA for 24 h, but
not 4 h, significantly increased the speed of both con-
trol- and dnRas-transfected cells. Thus, the expression
of dnRas was not able to prevent the VPA-induced
increase in the speed of BT4Cn cells.
Figure 5g shows an immunoblot of BT4Cn cells trea-
ted or untreated with VPA and/or the MEK inhibitor
PD98059. As expected, VPA increased the degree of
Erk1/2 phosphorylation compared with untreated cells
(Figure 5g, lanes 1 and 3). However, this stimulation
was prevented by treating the cells with PD98059 (Fig-
ure 5g, lane 4). Similarly, treatment of BT4Cn cells with
VPA increased the cell speed compared with untreated
cells (Figure 5h, columns 1 and 3). However, the VPA-
induced increase of the cell speed was completely
prevented by PD98059 (Figure 5h, column 3 vs. column
4), which reduced the speed of VPA-treated cells to the
level of control cells untreated with VPA and PD98059
(Figure 5h, columns 1 and 4). The same concentration
of PD98059 did not significantly reduce the speed of
cells untreated with VPA (Figure 5h, columns 1 and 2).
In conclusion, the data presented in Figure 5a-h
demonstrate that VPA in L929 and BT4Cn cells modu-
lates cell motility, cell morphology and the degree of
Erk1/2 phosphorylation by altering signaling through
the MAPK pathway downstream of Ras but upstream of
MEK (i.e., at the level of Raf).
Discussion
The observation that VPA is an HDAC inhibitor [6,23]
has spurred numerous studies demonstrating that VPA
possesses anti-cancer properties in vitro and in vivo
[2,5,24]. However, VPA affects the activities of several
enzymes and signal transduction pathways, and the
mechanisms underlying the anti-cancer properties of
VPA are not well characterized.
Consistent with earlier studies [25,26], we demon-
strated that the degree of VPA-induced histone H3 acet-
ylation was highly cell type-specific. Moreover, we found
that the effect of VPA on the degree of Erk1/2 phos-
phorylation was highly cell type-specific. This observa-
tion is in contrast to the general notion that VPA, as
demonstrated in several studies [17,27-30], activates
Erk1/2, although inhibition has also been reported [16].
HDAC inhibitors can inhibit Erk1/2 activity [31,32].
However, consistent with recent studies [29,33], no rela-
tionship was observed between HDAC inhibition and
the corresponding changes in the degree of Erk1/2
phosphorylation (Additional file 1, Figure S4). There-
fore, effects of VPA on the degree of Erk1/2 phosphory-
lation and HDAC inhibition seem to be independent
responses that, subsequently, may modulate biological
processes such as cell growth or motility through inde-
pendent mechanisms.
VPA-induced HDAC inhibition can hypothetically
affect cell motility. Thus, VPA has in some [34], but not
all [35], studies been shown to inhibit HDAC6, an
enzyme known to modulate cell motility [36]. Likewise,
VPA-induced HDAC inhibition can hypothetically affect
cell growth. However, we did not find any correlations
between the effects of VPA on HDAC activity and cell
motility or growth (Additional file 1, Figure S4).
Erk1/2 activity controls multiple processes, including
cell cycle progression, and cell growth, motility and sur-
vival [37]. Therefore, VPA-induced changes in Erk1/2
activity can hypothetically affect cell growth and moti-
lity. Hence, we focused our attention on the possible
relationship between VPA-induced changes in Erk1/2
activity, cell growth and motility.
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Cell growth can be inhibited by both a sustained
increase and decrease in Erk1/2 activity [37]. Therefore,
no general correlation was found between the effects of
VPA on the degree of Erk1/2 phosphorylation and cell
growth (Additional file 1, Figure S4). However, cell lines
demonstrating significant changes in the degree of Erk1/2
phosphorylation in response to VPA, generally had lower
IC50 values for growth than cell lines with unaffected
degrees of Erk1/2 phosphorylation (pERK-change, p <
0.05 and growth IC50 >3 mM, 0 cell lines; pERK-change,
p < 0.05 and growth IC50 <3 mM, 5 cell lines; pERK-
change, p > 0.05 and growth IC50 <3 mM, 4 cell lines;
pERK-change, p > 0.05 and growth IC50 >3 mM, 1 cell
line; p < 0.05; c2 and Fisher’s exact test). Therefore, we
hypothesize that the modulation of the degree of Erk1/2
phosphorylation by VPA is of central importance for
drug-mediated inhibition of cell inhibition.
We originally demonstrated VPA to inhibit the cell
speed [21]. However, consistent with later studies
[15,38,39], the present study shows that the effects of
VPA on the cell speed are highly cell type specific.
Interestingly, a time-response of the VPA-induced
change in L929 mean-cell speed exhibited a biphasic
response, with a significant reduction detectable already
after ~20 min followed by a further decrease after 24-48 h.
Hence, the initial, rapid response must be independent of
alterations in gene transcription, whereas the changes at
later time-points may be the result of alterations in gene
transcription.
The Ras-MAPK pathway regulates cell motility both
independent of, and as a result of, changes in gene tran-
scription [8]. However, Ras-MAPK signaling can affect dif-
ferent cell types differently. For example, VPA increased
the degree of Erk1/2 phosphorylation in BT4Cn and N2a
cells. However, BT4Cn cells maintained a de-differentiated
phenotype, and exhibited an increase in both lamellipodia
(Additional file 1, Figure S2 and Table S1) and the cell
speed, whereas N2a cells, known to differentiate in
response to a sustained increase in Erk1/2 activity [40],
consequently demonstrated a decrease in the cell speed
when exposed to VPA. Therefore, a direct correlation
between changes in the degree of Erk1/2 phosphorylation
and the cell speed is not to be expected and was not
observed (Additional file 1, Figure S4). Nevertheless, a
relationship was found since both L929 and BT4Cn cells
demonstrated opposite effects with respect to changes in
the degree of Erk1/2 phosphorylation and cell speed in
response to VPA. Moreover, in both cell lines the effect of
the drug on the Ras-MAPK pathway could be observed at
a position downstream of Ras but upstream of MEK (i.e.,
at the level of Raf). This observation is consistent with a
previous study in which abrogation of Ras signaling by pre-
venting the farnisylation of the protein did not affect VPA-
mediated activation of Erk1/2 in endothelial cells [29].
Raf exists in three isoforms, A-, B- and c-Raf [13],
which respond differently to Ras-independent upstream
activators. PKA can stimulate the activity of B-Raf but
inhibits the activity of c-Raf [41], which instead can be
activated by PKC [14]. Consequently, cell type-specific
effects of VPA on the degree of Erk1/2 phosphorylation
may be partially explained by cell type-specific differ-
ences in the expression of Raf isoforms. An analysis of
Raf expression revealed that all three Raf isoforms were
expressed in all 10 investigated cell lines, although at
highly variable levels (Additional file 1, Figure S3).
However, no apparent relationship was found between
the expression of the respective Raf isoforms and the
observed changes in the degree of Erk1/2 phosphoryla-
tion in response to VPA. Notably, constitutively acti-
vated B- and c-Raf mutations are frequently observed in
human cancers [42]. However, the analysis of Raf
expression did not include studies of Raf mutations, and
therefore the possibility that the expression of mutated
Raf isoforms can contribute to the observed results can-
not be excluded.
VPA has been suggested to be a possible chemothera-
peutic drug for the treatment of gliomas [4,5]. However,
consistent with recent observations [43], we found an
increase in the growth of the human glioma U87MG at
a physiologically relevant concentration of VPA. More-
over, the cell speed of the malignant glioma BT4Cn was
profoundly increased in response to VPA. These obser-
vations suggest that VPA should be used with caution
for the treatment of gliomas.
Conclusions
In conclusion, we demonstrate that VPA exposure
induced considerable cell type-specific effects on HDAC
inhibition, Erk1/2 phosphorylation, cell growth and
motility. Furthermore, Erk1/2 phosphorylation, cell
growth and motility are modulated independently of the
degree of HDAC inhibition. In contrast, VPA affects sig-
naling through the MAPK pathway at the level of Raf,
thereby modulating cell growth and motility. These
results suggest that the cell type-specific effects of VPA
on the activity of Erk1/2 are important in relation to the
use of VPA as an anti-cancer drug.
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